Go home shorts,it's over, page-152

Looking at the TEVA results, they seem to be very close to expectations, which is good. The following is an excerpt from the investor call from the CEO, I think it's encouraging when considering Mayne: "... in fact it won't let me copy! So here are the key points - Weakness in US generics are a result of 2 factors - 1. More generic competitors for CONCERTA (no impact to Mayne) and 2. The carry-over affect of 2017 price deflation... which they believe has shown stabilization, but has not had an immediate impact on Q2 results